Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On May2, 2017, Aerie Pharmaceuticals, Inc. (the Company) issued a
press release announcing its financial results for the first
quarter ended March31, 2017. A copy of the press release is
furnished as Exhibit 99.1 hereto and is hereby incorporated by
reference into this Item2.02.
The information in this Item2.02 (including Exhibit 99.1) shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended (the Securities Act), or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
The following exhibit relating to Item2.02 shall be deemed to be
furnished, and not filed:
99.1 Press Release dated May2, 2017.
About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Recent Trading Information
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) closed its last trading session down -1.75 at 42.10 with 397,520 shares trading hands.
